<DOC>
	<DOCNO>NCT00400569</DOCNO>
	<brief_summary>This open label single site Phase II clinical trial identify potentially promising therapy dose Sunitinib malate . The study drug take orally daily day 1 28 42 day cycle . Treatment continue either disease progression cumulative/acute toxicity . All patient unresectable metastatic soft tissue sarcoma ( STS ) : leiomyosarcoma , liposarcoma , fibrosarcoma , malignant fibrous histiocytoma ( MFH ) see Moffitt Cancer Center screen eligibility enrol study .</brief_summary>
	<brief_title>Phase II Study Sunitinib Malate Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma</brief_title>
	<detailed_description>This open label single site Phase II clinical trial identify potentially promising therapy dose Sunitinib malate , oral multi-kinase inhibitor . The study drug take orally daily day 1 28 42 day cycle . Treatment continue either disease progression cumulative/acute toxicity opinion treat physician trial Principal Investigator ( PI ) compromise ability patient receive treatment patient desire stop treatment . All patient unresectable metastatic STS : leiomyosarcoma , liposarcoma , fibrosarcoma , MFH see Moffitt Cancer Center screen eligibility enrol study . An office visit require begin every cycle every 6 week assess toxicity physical examination . Complete blood count ( CBC ) differential , comprehensive metabolic panel , electrocardiogram ( ECG ) obtain every scheduled visit .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Resolution acute toxic effect prior chemotherapy radiotherapy surgical procedure National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 grade less equal 1 . Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) less equal 2.5 x local laboratory upper limit normal ( ULN ) , AST ALT less equal 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin less equal 1.5 x ULN Absolute neutrophil count ( ANC ) great equal to1500/microL Platelets great equal 100,000/microL Hemoglobin great equal 9.0 g/dL Serum calcium less equal 12.0 mg/dL Serum creatinine less equal 1.5 x ULN Histologicallyproven liposarcoma , leiomyosarcoma , fibrosarcoma , MFH Measurable disease radiographically Disease deem surgically unresectable and/or metastatic Age great equal 18 year Life expectancy great 16 week Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Patients may 3 prior chemotherapy within 4 week start study treatment . Major surgery radiation therapy chemotherapy within 4 week start study treatment . NCI CTCAE version 3 grade 3 hemorrhage within 4 week start study treatment . History known brain metastasis , spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease . Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism Ongoing cardiac dysrhythmias NCI CTCAE great equal grade 2 Prolonged QTc interval baseline electrocardiogram ( ECG ) &gt; 500 msec . Hypertension control medication ( &gt; 150/100 mm Hg despite optimal medical therapy ) Prior tyrosine kinase inhibitor therapy Preexisting thyroid abnormality thyroid function maintain normal range medication Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection Concurrent treatment another clinical trial , except supportive care nontreatment trial Concomitant use agent know induce inhibit CYP3A4 Concomitant use agent metabolize cytochrome P450 system Ongoing treatment therapeutic dos Coumadin ( low dose Coumadin 2 mg mouth [ PO ] daily thromboprophylaxis allow ) Pregnancy breastfeed patient Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Sunitinib malate</keyword>
	<keyword>SUTENT</keyword>
	<keyword>SU011248</keyword>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>Gastrointestinal stromal tumor ( GIST )</keyword>
	<keyword>MFH</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Phase II</keyword>
</DOC>